About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Category Archives: Useful Resources
I don’t usually do adverts here on the blog – in fact never, but you may remember a posting I did a few months back on the communications implications of the Sunshine Act implementation. There is room to be expansive … Continue reading
Last Friday, May 2, at around 3 PM, the Centers for Disease Control and Prevention (CDC) in Atlanta held a press conference about the first detected case in the United States related to the coronavirus known as Middle East Respiratory … Continue reading
Last week I posted some of the latest legislative proposals out of the 113th Congress that would affect either some aspect of the pharma industry or FDA. That information is housed on a tab on the Eye on FDA site … Continue reading
As I mentioned last week, I have put together a data base – a constant work in progress – of pharma activities in social media. One of the fields on which I can perform sort on is one where I … Continue reading